Axellia acquires OTC maker
COPENHAGEN Axellia Pharmaceuticals on Tuesday announced its acquisition of the Phoenix Global Supply Group, based in White Plains, N.Y., to supply over-the-counter topical anti-infectives to the U.S. and Canadian markets.
“An important part of our strategy is to expand our offering to include finished products in targeted dosage forms and geographic markets,” said Axellia CEO Carl-Ake Carlsson, “while continuing to develop our core active pharmaceutical ingredients business.”
Phoenix’s initial product launches in North America are expected to include private-label offerings around bacitracin and polymyxin B sulfate, two of the major ingredients found in topical anti-infective first aid products.
“The Phoenix team is delighted to welcome Axellia as its majority owner. While there are many other manufacturers of over-the-counter antibiotic products, we believe that the U.S. and Canadian markets for these products continue to be attractive and provide a significant opportunity for Phoenix,” stated Walter Jenkins, Phoenix CEO.
FDA ‘actively pursuing’ McNeil Consumer Healthcare
WASHINGTON The Food and Drug Administration on Monday posted a media update to its Web page around the most recent McNeil Consumer Healthcare recall, suggesting that the entire McNeil Consumer Healthcare division has come under review.
“FDA is actively pursuing issues related to this recall,” the agency stated. “Drug safety analysts and other medical professionals at FDA have begun a comprehensive review of complaints received by the agency to determine the significance of any adverse events reported and any connection to the use of the recalled products. The FDA is conducting a company-wide investigation of McNeil Consumer Healthcare’s drug manufacturing practices to determine whether similar problems exist throughout the company and what additional steps the agency must take to ensure that these problems do not recur.”
In addition to increased regulatory scrutiny, the House Committee on Oversight and Government Reform on Friday announced it will hold a hearing addressing the latest McNeil recall on May 27 “to examine the circumstances surrounding the voluntary recall of over 40 over-the-counter variations of infant and children’s medicines produced by Johnson & Johnson/McNeil Consumer Healthcare.”
Expected to testify before that panel is Johnson & Johnson chairman and CEO Bill Weldon.
McNeil implemented a voluntary recall of its infant’s and children’s liquid drug products due to manufacturing deficiencies, which may have affected the quality, purity or potency of the drugs on April 30, the FDA noted. McNeil has also ceased production at its Fort Washington, Pa. facility. The agency also reiterated its belief that the chance of serious adverse health consequences associated with the recalled products is remote.
FORT MYERS, Fla. —The SilverCare personal monitor from SilverPlus was named by retailers attending the ECRM Home Health Care conference in March as the “hot new product” at the show.
The SilverCare monitor is a multifunctional, daily-living assistant, the company stated, with functions including a dedicated 911 button, a hands-free speaker and medication reminder in the body of a digital wristwatch. By 2011, SilverPlus hopes to launch a model that will include a motion sensor, which could trigger an alert due to a fall, for example. And by 2012, the SilverPlus vision is to fold its product line into a comprehensive and multifunctional telehealthcare tool, where remote healthcare professionals can help with disease and wellness management.
Each unit consists of a base console and wristwatch, and retails for a suggested $449, with no monthly service contract fee associated with the use of the product, the company added.